Status:
COMPLETED
Bridging the Docosahexaenoic Acid (DHA) Gap: The Effects of Omega-3 Fatty Acid Supplementation in Premature Infants
Lead Sponsor:
Sanford Health
Collaborating Sponsors:
The Gerber Foundation
Conditions:
Prematurity
Eligibility:
All Genders
24-33 years
Phase:
NA
Brief Summary
The purpose of this study is to understand if the "DHA gap" can be corrected by giving a daily dose of DHA oil to preterm babies. DHA is an essential omega-3 fatty acid, which means our body cannot m...
Detailed Description
Docosahexaenoic acid (DHA) is an essential fatty acid (FA) important for health and neurodevelopment. Premature infants are at risk of DHA deficiency and circulating levels directly correlate with hea...
Eligibility Criteria
Inclusion
- Preterm infants between 24 and 33 6/7 weeks gestation
- must be less than or equal to 1 week of age
Exclusion
- infants who are considered by the medical team to be non-viable
- infants with multiple or severe congenital anomalies such as gastroschisis, congenital chylothorax or other illnesses that do not allow a feeding tube to be placed or utilized at 7 days of age.
- term infants: who are born to mothers with diabetes or are small for gestational age (SGA-less than the 10th% for adjusted gestational age
- All families consented for this study will need to be able to read and write English
- Mother must be 18 years of age or older
- Taking Omegaven
Key Trial Info
Start Date :
October 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2014
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT01908907
Start Date
October 1 2012
End Date
February 1 2014
Last Update
March 21 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanford Health USD
Sioux Falls, South Dakota, United States, 57117